National Clinical Research Center of Cardiovascular Diseases, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, 100037, China
NCT Number: NCT07766434
This prospective, multicenter observational registry aims to establish a QFR-based quality control standard system for coronary revascularization in patients with coronary artery disease. The study will enroll over 10,000 patients with visually estimated at least one main branch coronary stenosis ≥50% from more than 50 centers across China (covering provincial, municipal, and county-level hospitals). Coronary angiographic images and intracoronary imaging (if available) will be collected and retrospectively analyzed by an independent core laboratory. The primary endpoint is QFR acquisition accessibility, defined as the mean of QFR usage proportion across centers.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Beijing, Beijing Municipality, 100037, China
This is a prospective, multicenter, observational registry study conducted at more than 50 centers across China. Patients with coronary angiography showing visually estimated at least one main branch stenosis ≥50% who undergo PCI or receive conservative treatment for acute coronary syndrome (including unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction >4 weeks after onset) or chronic coronary syndrome (including stable angina and asymptomatic myocardial ischemia) will be consecutively enrolled. Coronary angiographic images will be submitted to an independent core laboratory for retrospective QFR analysis. The study will establish a QFR-based quality control standard system for coronary revascularization.
Prespecified subgroup analyses will be performed to assess the concordance rates, overtreatment, and undertreatment rates between clinical decisions and offline core laboratory QFR, and to explore heterogeneity across hospital levels, clinical presentations, disease complexity, target vessel, operator annual PCI volume, QFR image analyzability, and lesion morphology. Other prespecified subgroups will be analyzed for the primary and secondary endpoints, including age, sex, diabetes, smoking status, acute coronary syndrome, body mass index, left ventricular ejection fraction, lesion location, length and reference vessel diameter, stenosis severity, multivessel disease, calcified lesion, bifurcation, tandem and bending/tortuous lesion, QFR gray zone (0.75-0.85), QFR based functional and residual functional SYNTAX score, residual QFR, center experience for invasive physiology, and learning experience with QFR.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: At enrollment (baseline)
Defined as the mean across participating centers of the proportion of patients undergoing QFR assessment among eligible patients at each center.
Time frame: 6 month, 1 year, 3 years, and 5 years
A composite of all-cause mortality, any myocardial infarction and any ischemia-driven revascularization
Time frame: 6 months, 1 year, 3 years, and 5 years
Cardiovascular, non-cardiovascular and undetermined death
Time frame: 6 months, 1 year, 3 years, and 5 years
Target vessel related and non-target vessel related MI
Time frame: 6 months, 1 year, 3 years, and 5 years
The ischemia driven and non-ischemia driven TVR
Time frame: 6 months, 1 year, 3 years, and 5 years
The ischemia driven and non-ischemia driven Revascularization
Time frame: 6 months, 1 year, 3 years, and 5 years
Definite and probable stent thrombosis during acute, sub-acute, late, and very late phase according to the Academic Research Consortium (ARC)-2
Contact information is provided by the study sponsor or research team.
China National Center for Cardiovascular Diseases
Other Gov
Acronym: QFR-REAL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07762755
Arterial Occlusive Diseases, Arteriosclerosis
Beijing, Beijing Municipality, China
View Trial DetailsNCT07762898
Arterial Occlusive Diseases, Arteriosclerosis
Lanzhou, Gansu, China
View Trial DetailsNCT07760129
Acute Kidney Injury, Arterial Occlusive Diseases
View Trial DetailsNCT07761624
Arterial Occlusive Diseases, Arteriosclerosis
Diyarbakır, Turkey (Türkiye)
View Trial Details